Advertisement
INCY vs INSM
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Insmed Incorporated (INSM) Stock Comparison
Key Takeaways
- INCY reported Q4 2025 revenue growth of 28% to $1.51 billion, driven by Jakafi and Opzelura, but shares dipped on conservative 2026 guidance for Opzelura.
- INSM showcased strong Brinsupri launch with $144.6 million in Q4 2025 sales, guiding at least $1 billion for 2026, fueling optimism despite wider losses.
- Both biotech firms focus on serious diseases, but INCY offers profitability with a P/E of ~15.6 and $20B market cap, while INSM trades at higher valuation (~$32B cap) on growth potential.
- INSM delivered superior 1-year returns (~88%), but recent volatility contrasts INCY's stability near 52-week highs.
- Analysts rate both positively, with INSM at Strong Buy (target $189) and INCY at Buy (target $107).
Introduction
Incyte Corporation (INCY) and Insmed Incorporated (INSM) represent compelling options in the biotechnology sector, both targeting therapies for oncology, inflammation, and rare pulmonary diseases. This stock comparison evaluates their recent financial results, pipeline momentum, and market positioning amid evolving biotech sentiment. Traders seeking growth with volatility may eye INSM's blockbuster potential, while investors favoring established revenue streams might prefer INCY's profitability. Understanding relative performance aids in assessing risks and opportunities in this dynamic market.
INCY Overview and Recent Performance
Incyte Corporation (INCY), a global biopharmaceutical firm, discovers, develops, and commercializes therapeutics for oncology and inflammation, with flagship products Jakafi and Opzelura driving growth. In recent market activity, INCY shares hovered around $100, near 52-week highs of $112, reflecting a solid YTD gain of about 1-2% and robust 1-year performance. Q4 2025 earnings highlighted 28% revenue surge to $1.51 billion, beating estimates, fueled by Jakafi sales and Opzelura uptake in dermatology. However, conservative 2026 guidance for Opzelura ($750-790M) and an EPS miss triggered an 8% pullback, tempering sentiment. Pipeline advances, including povorcitinib Phase 3 data and 14 pivotal trials planned, support diversification beyond Jakafi amid patent considerations. Analysts maintain bullish targets around $107, citing core ex-Jakafi growth of ~30%.
INSM Overview and Recent Performance
Insmed Incorporated (INSM), a biopharmaceutical company, focuses on therapies for serious rare diseases, particularly pulmonary conditions, with ARIKAYCE and newly launched Brinsupri as key assets. Trading near $149 with a $32B market cap, INSM has shown volatility, down ~6% recently but up ~88% over the past year despite YTD softness. Recent quarters featured Brinsupri's explosive debut, generating $144.6M in Q4 2025 and $173M full-year, exceeding expectations with over 2,500 patients. Management guided at least $1B in 2026 Brinsupri revenue and $450-470M for ARIKAYCE, projecting total revenue doubling to $1.45B. Despite wider losses ($1.28B full-year), strong Japan/Europe growth and upcoming ENCORE Phase 3 data bolster momentum. Analyst consensus leans Strong Buy with $189 targets, emphasizing launch execution.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and sectors. These bots, powered by advanced AI models, are selected based on real-time performance in current market conditions, featuring metrics like annualized returns up to +254%, win rates of 54-94%, profit factors to 35+, and profit-to-drawdown ratios exceeding 11. Highlights include semiconductor bots at +98% returns (70% win rate) and aerospace/defense strategies at +123% (75% win rate), often outperforming the S&P 500 recently through momentum and volatility plays. With varying styles from short-term (2D holds) to multi-asset portfolios, they offer risk-managed copy trading options. Explore Trending AI Robots to identify suitable bots for your portfolio.
Head-to-Head Comparison
INCY and INSM both operate in biotech, but diverge in business models: INCY leverages a mature portfolio with profitable oncology/dermatology drugs, generating $5.14B 2025 revenue, while INSM emphasizes rare disease launches like Brinsupri, scaling from $606M revenue. Growth drivers contrast—INCY's pipeline diversification tempers Jakafi reliance; INSM bets on blockbuster Brinsupri expansion. Recent momentum favors INSM's launch hype over INCY's post-earnings dip, though INCY exhibits lower beta (0.85 vs. 1.12). Risks include INCY's patent cliffs and INSM's losses; sentiment tilts growth-oriented for INSM, stability for INCY.
Tickeron AI Verdict
Tickeron’s AI currently favors INSM for its superior trend consistency via Brinsupri's rapid uptake and aggressive 2026 guidance signaling catalysts like ENCORE data, positioning it strongly in high-growth rare disease niches despite volatility. INCY offers stability and profitability, but relative momentum lags post-guidance. Probabilistic edge to INSM in prevailing biotech rotation toward launches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and INSM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 5 bearish.
- INSM’s TA Score: 4 bullish, 6 bearish.
Price Growth
INCY (@Biotechnology) experienced а -3.30% price change this week, while INSM (@Biotechnology) price change was +7.69% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.25%. For the same industry, the average monthly price growth was -2.77%, and the average quarterly price growth was +7.50%.
Reported Earning Dates
INCY is expected to report earnings on Aug 04, 2026.
INSM is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (-2.25% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INCY | INSM | INCY / INSM | |
| Capitalization | 19B | 23.7B | 80% |
| EBITDA | 1.87B | -1.08B | -173% |
| Gain YTD | -3.503 | -37.290 | 9% |
| P/E Ratio | 13.46 | N/A | - |
| Revenue | 5.36B | 820M | 654% |
| Total Cash | 4.02B | 1.22B | 328% |
| Total Debt | 39.4M | 580M | 7% |
INCY | INSM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 79 | 59 | |
SMR RATING 1..100 | 32 | 100 | |
PRICE GROWTH RATING 1..100 | 52 | 65 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (68) in the Biotechnology industry is in the same range as INSM (73). This means that INCY’s stock grew similarly to INSM’s over the last 12 months.
INSM's Profit vs Risk Rating (59) in the Biotechnology industry is in the same range as INCY (79). This means that INSM’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is significantly better than the same rating for INSM (100). This means that INCY’s stock grew significantly faster than INSM’s over the last 12 months.
INCY's Price Growth Rating (52) in the Biotechnology industry is in the same range as INSM (65). This means that INCY’s stock grew similarly to INSM’s over the last 12 months.
INCY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as INSM (100). This means that INCY’s stock grew similarly to INSM’s over the last 12 months.
| INCY | INSM | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 75% |
| Stochastic ODDS (%) | 3 days ago 66% | 3 days ago 79% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 84% |
| MACD ODDS (%) | 3 days ago 63% | 4 days ago 75% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 62% | 3 days ago 78% |
| Advances ODDS (%) | 7 days ago 62% | 5 days ago 71% |
| Declines ODDS (%) | 3 days ago 60% | 3 days ago 73% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 84% |
| Aroon ODDS (%) | 3 days ago 63% | 3 days ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OILU | 47.64 | 2.88 | +6.42% |
| MicroSectorsTM Oil&Gs Exp&Pd 3X Lvg ETNs | |||
| OSCX | 75.65 | 1.08 | +1.44% |
| Defiance Daily Target 2x Long OSCR ETF | |||
| RAAA | 25.12 | 0.02 | +0.06% |
| Reckoner Yield Enhanced AAA CLO ETF | |||
| FLTB | 50.11 | -0.17 | -0.33% |
| Fidelity Limited Term Bond ETF | |||
| TSPA | 46.76 | -0.62 | -1.31% |
| T. Rowe Price US Equity Research ETF | |||
INCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with BMRN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
|---|---|---|---|---|
| INCY | 100% | -2.38% | ||
| BMRN - INCY | 43% Loosely correlated | -2.69% | ||
| PTCT - INCY | 41% Loosely correlated | -1.72% | ||
| TECH - INCY | 39% Loosely correlated | -3.22% | ||
| AXON - INCY | 39% Loosely correlated | +0.95% | ||
| REGN - INCY | 37% Loosely correlated | -2.05% | ||
More | ||||
INSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | -5.60% | ||
| CNTN - INSM | 74% Closely correlated | -3.47% | ||
| TRDA - INSM | 44% Loosely correlated | -6.59% | ||
| ENGN - INSM | 42% Loosely correlated | -4.97% | ||
| AXON - INSM | 40% Loosely correlated | +0.95% | ||
| ARRY - INSM | 40% Loosely correlated | +4.06% | ||
More | ||||